Cargando…

Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events

This analysis sought to assess the clinical predictivity of an in vitro assay which utilized the human B‐lymphoma BJAB cell line, for identification of antisense oligonucleotides (ASOs) with the potential to elicit innate immune activation in humans. Adverse events (AEs) from clinical trial data wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Partridge, Wesley, Burel, Sebastien A., Ferng, Annie, Xia, Shuting, Kwoh, T. Jesse, Henry, Scott P., Baker, Brenda F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087069/ https://www.ncbi.nlm.nih.gov/pubmed/36631935 http://dx.doi.org/10.1111/cts.13476

Ejemplares similares

Improvements in the Tolerability Profile of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods
por: Partridge, Wesley, et al.
Publicado: (2021)

Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023)

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
por: Crooke, Stanley T, et al.
Publicado: (2016)

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
por: Viney, Nicholas J., et al.
Publicado: (2020)

Proteomics and Transcriptomics of BJAB Cells Expressing the Epstein-Barr Virus Noncoding RNAs EBER1 and EBER2
por: Pimienta, Genaro, et al.
Publicado: (2015)

Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus
por: Arcenas, Rodney C, et al.
Publicado: (2002)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015)

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
por: Crooke, Stanley T., et al.
Publicado: (2017)

Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile
por: Chin, M, et al.
Publicado: (2009)

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
por: Goyenvalle, Aurélie, et al.
Publicado: (2023)

Antisense technology: A review
por: Crooke, Stanley T., et al.
Publicado: (2021)

Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses
por: Han, Kelong, et al.
Publicado: (2022)

Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling
por: Moisan, Annie, et al.
Publicado: (2017)

Ranking Adverse Drug Reactions With Crowdsourcing
por: Gottlieb, Assaf, et al.
Publicado: (2015)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
por: Crooke, Stanley T., et al.
Publicado: (2019)

Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics
por: Lee, Richard G., et al.
Publicado: (2013)

IFACEwat: the interfacial water-implemented re-ranking algorithm to improve the discrimination of near native structures for protein rigid docking
por: Su, Chinh Tran-To, et al.
Publicado: (2014)

Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
por: Hua, Yimin, et al.
Publicado: (2007)

Evaluation of kernel low-rank compressed sensing in preclinical diffusion magnetic resonance imaging
por: de Souza, Diego Alves Rodrigues, et al.
Publicado: (2023)

A conventional PKC critical for both the light-dependent and the light-independent regulation of the actin cytoskeleton in Drosophila photoreceptors
por: Shieh, Bih-Hwa, et al.
Publicado: (2023)

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
por: van Putten, Maaike, et al.
Publicado: (2014)

Optimized design of antisense oligomers for targeted rRNA depletion
por: Phelps, Wesley A, et al.
Publicado: (2020)

Natural antisense transcripts as drug targets
por: Khorkova, Olga, et al.
Publicado: (2022)

Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer
por: Lara, Olivia D., et al.
Publicado: (2020)

Correction to ‘Optimized design of antisense oligomers for targeted rRNA depletion’
por: Phelps, Wesley A, et al.
Publicado: (2021)

Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets
por: Maciejewski, Mateusz, et al.
Publicado: (2017)

Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial
por: Yuen, Man-Fung, et al.
Publicado: (2021)

A Sensitive Assay System To Test Antisense Oligonucleotides for Splice Suppression Therapy in the Mouse Liver
por: Gallego-Villar, Lorena, et al.
Publicado: (2014)

Prediction of Drug Efficacy in Colon Cancer Preclinical Models Using a Novel Ranking Method of Gene Expression
por: Fritz, Justine, et al.
Publicado: (2020)

Standardization of the Filovirus Plaque Assay for Use in Preclinical Studies
por: Shurtleff, Amy C., et al.
Publicado: (2012)

Validation of the Filovirus Plaque Assay for Use in Preclinical Studies
por: Shurtleff, Amy C., et al.
Publicado: (2016)

Optimization of the TeraTox Assay for Preclinical Teratogenicity Assessment
por: Jaklin, Manuela, et al.
Publicado: (2022)

The Effects of 2′-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
por: Crooke, Stanley T., et al.
Publicado: (2018)

Cautious Label-Wise Ranking with Constraint Satisfaction
por: Carranza-Alarcon, Yonatan-Carlos, et al.
Publicado: (2020)

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
por: Burel, Sebastien A., et al.
Publicado: (2016)

MIRTH: Metabolite Imputation via Rank-Transformation and Harmonization
por: Freeman, Benjamin A., et al.
Publicado: (2022)

Detection, characterization and regulation of antisense transcripts in HIV-1
por: Landry, Sébastien, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_550qeg1er5ece31gmq67uitgsc